Skip to Main Content

Author Details

Scott H Kaufmann
Mayo Clinic
1977
404
100
PMIDPaper TitleJournal TitlePublished Year
36376382A BAK subdomain that binds mitochondrial lipids selectively and releases cytochrome C.Cell Death Differ2023
37960985A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.Cancer Med2023
37823600ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance.Nucleic Acids Res2023
37821702Apoptotic stress causes mtDNA release during senescence and drives the SASP.Nature2023
37550562PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.Oncogene2023
37541199Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.Cell2023
37393297Eltrombopag directly activates BAK and induces apoptosis.Cell Death Dis2023
37380808How CHKing ROS signaling preserves genomic integrity.Cell Res2023
37193683Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.Blood Cancer J2023
36639731Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response.Sci Rep2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36376382A BAK subdomain that binds mitochondrial lipids selectively and releases cytochrome C.Cell Death Differ2023
36315007Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.Blood Adv2023
37960985A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.Cancer Med2023
37550562PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.Oncogene2023
37541199Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.Cell2023
37823600ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance.Nucleic Acids Res2023
37821702Apoptotic stress causes mtDNA release during senescence and drives the SASP.Nature2023
37393297Eltrombopag directly activates BAK and induces apoptosis.Cell Death Dis2023
37193683Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.Blood Cancer J2023
37380808How CHKing ROS signaling preserves genomic integrity.Cell Res2023
36639731Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response.Sci Rep2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36315007Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.Blood Adv2023
34654724Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer.Cancer Res2022
36099300Homologous recombination-deficient mutation cluster in tumor suppressor <i>RAD51C</i> identified by comprehensive analysis of cancer variants.Proc Natl Acad Sci U S A2022
35931981DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer.BMC Bioinformatics2022
35490622Correction: High cell surface death receptor expression determines type I versus type II signaling.J Biol Chem2022
35472731Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors.Transl Oncol2022
35435472A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.Cancer Chemother Pharmacol2022
35359437Uncovering Pharmacological Opportunities for Cancer Stem Cells-A Systems Biology View.Front Cell Dev Biol2022
34906376Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.Gynecol Oncol2022
34810199Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.Cancer Res2022
34654724Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer.Cancer Res2022
34600126Manifold medicine: A schema that expands treatment dimensionality.Drug Discov Today2022
35472731Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors.Transl Oncol2022
35435472A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.Cancer Chemother Pharmacol2022
35490622Correction: High cell surface death receptor expression determines type I versus type II signaling.J Biol Chem2022
35359437Uncovering Pharmacological Opportunities for Cancer Stem Cells-A Systems Biology View.Front Cell Dev Biol2022
35931981DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer.BMC Bioinformatics2022
36099300Homologous recombination-deficient mutation cluster in tumor suppressor <i>RAD51C</i> identified by comprehensive analysis of cancer variants.Proc Natl Acad Sci U S A2022
34906376Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.Gynecol Oncol2022
34810199Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.Cancer Res2022
34600126Manifold medicine: A schema that expands treatment dimensionality.Drug Discov Today2022
32905653Circulating CD14<sup>+</sup> HLA-DR<sup>lo/-</sup> monocytic cells as a biomarker for epithelial ovarian cancer progression.Am J Reprod Immunol2021
33592542USP13 regulates the replication stress response by deubiquitinating TopBP1.DNA Repair (Amst)2021
33519255The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study.Blood Lymphat Cancer2021
33414171CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.Cancer Res2021
32905653Circulating CD14<sup>+</sup> HLA-DR<sup>lo/-</sup> monocytic cells as a biomarker for epithelial ovarian cancer progression.Am J Reprod Immunol2021
35028612Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.Cell Rep Med2021
  • 1 - 50 of 808

Recommended Authors

Jordi Carreras Puigvert
Department of Pharmaceutical Biosciences, Uppsala University
Career Start Year 2009
Number of shared co-authors 0
Andrea Newbold
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 1
St??phanie Solier
Gustave Roussy Cancer Center, INSERM U1170
Career Start Year 2002
Number of shared co-authors 2
Chandra C Ghosh
The Wistar Institute
Career Start Year 1999
Number of shared co-authors 0
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 2
Nhu-An Pham
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1998
Number of shared co-authors 1
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Ute Fischer
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 0
Ricky W Johnstone
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 6
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 3
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 10
Lawrence H Boise
Winship Cancer Institute, Emory University
Career Start Year 1988
Number of shared co-authors 7
Richard B Lock
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Career Start Year 1987
Number of shared co-authors 2
Lori S Hart
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 1
David J McConkey
Johns Hopkins School of Medicine
Career Start Year 1986
Number of shared co-authors 3
Daniel E Johnson
University of California San Francisco
Career Start Year 1985
Number of shared co-authors 1
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 2
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 10
Patrick Auberger
Universite Cote d'Azur, INSERM U5
Career Start Year 1982
Number of shared co-authors 5
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 11
Fabien Calvo
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 3
Luke Whitesell
University of Toronto
Career Start Year 1979
Number of shared co-authors 1
Robert H Shoemaker
National Cancer Institute
Career Start Year 1978
Number of shared co-authors 2
Wolfgang E Berdel
University Hospital Munster
Career Start Year 1976
Number of shared co-authors 1
David W Hedley
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1975
Number of shared co-authors 4
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 9
Paul Workman
The Institute of Cancer Research
Career Start Year 1974
Number of shared co-authors 2
Stephen B Howell
Moores Cancer Center and Department of Medicine, University of California
Career Start Year 1974
Number of shared co-authors 2
Peter J Houghton
The University of Texas Health Science Center at San Antonio
Career Start Year 1971
Number of shared co-authors 5
John N Weinstein
The University of Texas MD Anderson Cancer Center
Career Start Year 1968
Number of shared co-authors 17

Collaborators

Cristina Correia
Co-authored papers 21
Ann L Oberg
Co-authored papers 19
Saravut J Weroha
Mayo Clinic
Co-authored papers 15
Paul Haluska
Mayo Clinic
Co-authored papers 12
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 10
Iain A McNeish
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 10
Melissa C Larson
Mayo Clinic
Co-authored papers 9
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 8
Jeff A Sloan
Mayo Clinic
Co-authored papers 7
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 7
Daniel D Billadeau
Co-authored papers 7
David P Steensma
Novartis Institutes for BioMedical Research
Co-authored papers 7
Anna DeFazio
Westmead Hospital
Co-authored papers 7
Isabelle Ray-Coquard
University Claude Bernard Lyon I
Co-authored papers 7
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Co-authored papers 6
Michael J Birrer
Co-authored papers 6
Gary L Keeney
Mayo Clinic
Co-authored papers 6
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 6
Nadia Traficante
Peter MacCallum Cancer Centre
Co-authored papers 6
Michael E Carney
John A. Burns School of Medicine, University of Hawaii
Co-authored papers 5
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 5
Chen Wang
Center for Individualized Medicine, Mayo Clinic
Co-authored papers 5
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 5
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 5
Stacey J Winham
Mayo Clinic
Co-authored papers 5
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 5
Steven R Alberts
Mayo Clinic
Co-authored papers 5
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 5
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 5
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Co-authored papers 5
Release 1.2